The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
V. I. Deigin and colleagues · 2024 · International Journal of Molecular Sciences. 25(9):5042
Study data at a glance
- Participants or experimental model
- Review of chiral peptide pharmacology
- Reported results
- The review contrasts immune stimulation and suppression across peptide stereochemistry and discusses lymphocyte activation and marrow distribution.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Narrative synthesis is not independent clinical replication.
- Radiolabel tissue exposure is not proof of intact-peptide targeting or selective suppression of autoreactive cells.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Open-access review checked for identity distinctions and mechanistic context.
Recorded source-check date: 2026-11-05. This date does not imply a completed systematic review.
Open original source or index record ↗
DOI: 10.3390/ijms25095042
Citation and original source
Original source: V. I. Deigin and colleagues. The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples International Journal of Molecular Sciences. 25(9):5042 2024.
Molekul research summary: https://molekul.io/research/auto-chiral-peptides-review-2024. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymogen
EW is discussed in the thymus-derived research program. Thymalin extract outcomes cannot be assigned to this defined peptide.
Thymodepressin
Synthetic γ-D-Glu-D-Trp immunosuppressive dipeptide. Russian reports cover psoriasis, autoimmune cytopenias and myositis; a rheumatoid arthritis trial registration has no verified results.